Amgen licenses Immunomedics' cancer antibody; terminated
Executive Summary
Amgen has licensed from Immunomedics (cancer and infectious disease diagnostics and therapeutics) a humanized monoclonal antibody, LymphoCide (epratuzumab), in Phase III to treat non-Hodgkin's lymphoma. It will pay (uf)$18mm up front, up to $65mm in clinical milestones, and one-time sales milestones of $50-225mm if net sales reach between $500mm to $1bn.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice